Ixazomib can effectively inhibit both activation pathways of NF-κB in MM stromal cells.554 Ixazomib is often used in combination with other anticancer drugs and has shown significant efficacy in clinical trials for the treatment of multiple myeloma. Here, NFKB1 is linked to AL amyloidosis.